Pingyu Chen

China Pharmaceutical University

H指数:9

被引数:196

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Treatment Preferences in Attention Deficit Hyperactivity Disorder: A Systematic Review of Discrete Choice Experiment and Best-Worst Scaling Studies

注意缺陷多动障碍的治疗偏好：离散选择实验和最佳-最差标度研究的系统综述

Journal of Attention Disorders

IF2.2

2026-11-030

PRE

Efficacy and safety of immunotherapy-based combination therapy as first-line treatment for advanced renal cell carcinoma: a systematic review and network meta-analysis

基于免疫治疗的联合疗法作为晚期肾细胞癌一线治疗的有效性与安全性：系统评价和网络Meta分析

Medical Oncology

IF3.5

2026-07-220

PRE

Domain-specific discounting of health and money: implications for health technology assessment

特定领域的健康与金钱折扣：对卫生技术评估的启示

The European Journal of Health Economics

IF0

2026-05-230

PRE

Factors influencing the cost-effectiveness of novel oral anticoagulants compared to vitamin K antagonists in patients with atrial fibrillation: a systematic review

影响新型口服抗凝药相较于维生素K拮抗剂在房颤患者中成本效益的因素：一项系统评价

FRONTIERS IN PHARMACOLOGY

IF4.8

2025-03-280

Wealth gradients in healthy aging: evidence from the 2011 and 2013 waves of the China Health and Retirement Longitudinal Study

健康老龄化中的财富梯度：来自中国健康与退休纵向研究2011年和2013年波次的证据

ARCHIVES OF PUBLIC HEALTH

IF3.2

2025-02-210

Comparison of the EQ-5D-Y and the CHU-9D instruments in a general child population based on self-reports and proxy-reports

EUROPEAN JOURNAL OF HEALTH ECONOMICS

IF3

2024-09-280

PRE

Methods for Economic Evaluations of Novel Oral Anticoagulants in Patients with Atrial Fibrillation: A Systematic Review

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2023-10-291

PRE

The autoactivation of human single-chain urokinase-type plasminogen activator (uPA)

JOURNAL OF BIOLOGICAL CHEMISTRY

IF3.9

2023-10-012

OAAI

Health utilities in pediatric cancer patients and survivors: a systematic review and meta-analysis for clinical implementation (vol 31, pg 343, 2022)

QUALITY OF LIFE RESEARCH

IF2.7

2022-11-110

Economic evaluation of sintilimab plus chemotherapy vs. pembrolizumab plus chemotherapy for the treatment of first-line advanced or metastatic squamous NSCLC

FRONTIERS IN PUBLIC HEALTH

IF3.4

2022-08-0920

OAAI

Predictors of Quality of Life in Patients With Myocardial Infarction Combined With Dyslipidemia

FRONTIERS IN PUBLIC HEALTH

IF3.4

2021-10-067

OAAI

Health utilities in pediatric cancer patients and survivors: a systematic review and meta-analysis for clinical implementation

QUALITY OF LIFE RESEARCH

IF2.7

2021-07-057

PREAI

FRONTIERS IN PUBLIC HEALTH

IF3.4

2021-06-098

OAAI

Cost-Effectiveness Analysis of Abemaciclib Plus Fulvestrant in the Second-Line Treatment of Women With HR+/HER2-Advanced or Metastatic Breast Cancer: A US Payer Perspective

Abemaciclib联合氟维司群在HR /HER2-Advanced或转移性乳腺癌妇女二线治疗中的成本效益分析: 美国付款人视角

FRONTIERS IN MEDICINE

IF3

2021-06-0219

OAAI

Economic Burden of Myocardial Infarction Combined With Dyslipidemia

FRONTIERS IN PUBLIC HEALTH

IF3.4

2021-02-1910

OAAI

A comparison of self-reported and proxy-reported health utilities in children: a systematic review and meta-analysis

HEALTH AND QUALITY OF LIFE OUTCOMES

IF3.4

2021-02-0521

OAAI

Cost-Effectiveness Analysis of Oral Direct-Acting Antivirals for Chinese Patients with Chronic Hepatitis C

APPLIED HEALTH ECONOMICS AND HEALTH POLICY

IF3.3

2020-11-195

PREAI

Pingyu Chen

个人简介

教育背景

工作经历

荣誉奖项

研究方向